Professor Jianchun Duan: Personalized Neoantigen DC Vaccine LK101 Plus Immunotherapy—Exploring a New First-Line Maintenance Strategy for NSCLC
Immunotherapy combined with chemotherapy has become the standard first-line treatment for driver gene-negative non-small cell lung cancer (NSCLC). However, owing to the heterogeneity of the tumor immune microenvironment and complex mechanisms of primary and acquired resistance, the efficacy of existing regimens has reached a plateau, with only limited improvements in patient survival. How to optimize first-line maintenance strategies and overcome treatment resistance has therefore become a key clinical challenge. Therapeutic cancer vaccines offer a promising approach to addressing this unmet need by stimulating specific antitumor immune responses.









